ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:ABMD
- CUSIP: 00365410
- Web: www.abiomed.com
Capitalization:- Market Cap: $7.23099 billion
- Outstanding Shares: 44,102,000
Average Prices:- 50 Day Moving Avg: $152.81
- 200 Day Moving Avg: $138.79
- 52 Week Range: $95.14 - $164.60
P/E:- Trailing P/E Ratio: 95.88
- Foreward P/E Ratio: 63.06
- P/E Growth: 2.55
Sales & Book Value:- Annual Revenue: $474.78 million
- Price / Sales: 15.23
- Book Value: $12.86 per share
- Price / Book: 12.75
Profitability:- EBIDTA: $110.92 million
- Net Margins: 16.13%
- Return on Equity: 13.03%
- Return on Assets: 10.98%
Debt:- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 5.95%
- Quick Ratio: 5.32%
Misc:- Average Volume: 298,842 shs.
- Beta: 0.22
- Short Ratio: 4.61
Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, July, 27th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.03. The firm earned $132.47 million during the quarter, compared to the consensus estimate of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business's revenue for the quarter was up 28.6% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. View ABIOMED's Earnings History.
When will ABIOMED make its next earnings announcement?
Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?
7 brokers have issued 1-year price objectives for ABIOMED's stock. Their forecasts range from $140.00 to $175.00. On average, they expect ABIOMED's stock price to reach $157.50 in the next year. View Analyst Ratings for ABIOMED.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY) and ViewRay (VRAY).
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
- Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
- David M. Weber, Chief Operating Officer
- William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
- Andrew J. Greenfield, Vice President, General Manager - Global Marketing
- Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
- Dorothy E. Puhy, Lead Independent Director
- Jeannine M. Rivet, Independent Director
- Eric A. Rose M.D., Independent Director
- Martin P. Sutter, Independent Director
Who owns ABIOMED stock?
ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional investors include
PRIMECAP MANAGEMENT COMPANY
(9.85%), BlackRock Inc. (7.69%), Vanguard Group Inc. (7.56%), Baillie Gifford & Co. (4.49%), Palo Alto Investors LLC (4.45%) and State Street Corp (2.44%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Who sold ABIOMED stock? Who is selling ABIOMED stock?
ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Voya Investment Management LLC, Jackson Square Partners LLC, Russell Investments Group Ltd., William Blair Investment Management LLC, Macquarie Group Ltd., Arrowstreet Capital Limited Partnership and Marshall Wace North America L.P.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Paul Thomas. View Insider Buying and Selling for ABIOMED.
Who bought ABIOMED stock? Who is buying ABIOMED stock?
ABIOMED's stock was acquired by a variety of institutional investors in the last quarter, including Koch Industries Inc., Baillie Gifford & Co., FMR LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, State Treasurer State of Michigan, BlackRock Inc. and Castleark Management LLC. View Insider Buying and Selling for ABIOMED.
How do I buy ABIOMED stock?
Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABIOMED stock can currently be purchased for approximately $163.96.
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ABIOMED (NASDAQ:ABMD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 6 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.86) |
| Consensus Price Target: | $157.50 (3.94% downside) |
Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/29/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $160.00 | Low |  |
| 8/29/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $175.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $135.00 -> $140.00 | Low | |
| 6/8/2017 | William Blair | Reiterated Rating | Outperform -> Outperform | | Low | |
| 3/30/2017 | Leerink Swann | Boost Price Target | Outperform | $140.00 -> $150.00 | Low | |
| 1/8/2017 | BTIG Research | Reiterated Rating | Buy | $170.00 | N/A | |
| 12/6/2016 | Guggenheim | Initiated Coverage | Buy | $150.00 | N/A | |
| 4/10/2016 | Benchmark Co. | Reiterated Rating | Buy | $145.00 | N/A | |
| 10/30/2015 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | $85.00 | N/A | |
| 10/29/2015 | Sterne Agee CRT | Reiterated Rating | Buy | | N/A | |
(Data available from 9/26/2015 forward)
Earnings History for ABIOMED (NASDAQ:ABMD)Earnings History by Quarter for ABIOMED (NASDAQ ABMD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.36 | | | | | N/A | |
| 7/27/2017 | Q1 2018 | $0.42 | $0.45 | $130.83 million | $132.47 million | View | N/A | |
| 5/4/2017 | Q4 2017 | $0.33 | $0.33 | $122.82 million | $124.68 million | View | Listen | |
| 1/26/2017 | Q317 | $0.29 | $0.34 | $112.71 million | $114.70 million | View | Listen | |
| 10/27/2016 | Q217 | $0.24 | $0.20 | $103.16 million | $103.00 million | View | Listen | |
| 7/28/2016 | Q117 | $0.23 | $0.29 | $97.23 million | $103.00 million | View | Listen | |
| 5/3/2016 | Q416 | $0.19 | $0.24 | $90.52 million | $94.00 million | View | N/A | |
| 2/4/2016 | Q316 | $0.15 | $0.23 | $80.04 million | $85.80 million | View | Listen | |
| 10/29/2015 | Q2 | $0.13 | $0.17 | $74.56 million | $76.30 million | View | Listen | |
| 8/4/2015 | Q116 | $0.08 | $0.20 | $66.27 million | $73.40 million | View | N/A | |
| 5/5/2015 | Q415 | $0.12 | $0.28 | $62.55 million | $67.60 million | View | N/A | |
| 1/27/2015 | Q315 | $0.03 | $0.30 | $53.20 million | $62.00 million | View | N/A | |
| 10/30/2014 | Q215 | $0.02 | $0.09 | $48.80 million | $51.80 million | View | N/A | |
| 7/31/2014 | Q115 | $0.02 | ($0.04) | $297.10 million | $48.80 million | View | N/A | |
| 5/1/2014 | Q414 | $0.09 | $0.09 | $50.93 million | $50.40 million | View | N/A | |
| 1/31/2014 | Q314 | $0.05 | $0.11 | $46.00 million | $46.20 million | View | N/A | |
| 11/6/2013 | Q214 | $0.03 | $0.03 | $43.75 million | $44.30 million | View | N/A | |
| 8/1/2013 | Q1 2014 | $0.06 | ($0.04) | $42.93 million | $42.70 million | View | N/A | |
| 5/2/2013 | Q4 2013 | $0.08 | $0.09 | $41.87 million | $43.70 million | View | N/A | |
| 2/6/2013 | Q3 2013 | $0.07 | $0.07 | $38.04 million | $38.30 million | View | N/A | |
| 11/1/2012 | Q213 | $0.05 | $0.20 | $37.47 million | $37.40 million | View | N/A | |
| 8/2/2012 | | $0.10 | $0.16 | | | View | N/A | |
| 5/16/2012 | | $0.07 | $0.07 | | | View | N/A | |
| 2/3/2012 | | ($0.01) | $0.07 | | | View | N/A | |
| 11/3/2011 | | ($0.09) | $0.02 | | | View | N/A | |
| 8/4/2011 | | ($0.06) | ($0.03) | | | View | N/A | |
| 5/18/2011 | | ($0.04) | ($0.05) | | | View | N/A | |
| 2/3/2011 | | ($0.09) | ($0.02) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ABIOMED (NASDAQ:ABMD)2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.78
2019 EPS Consensus Estimate: $2.47
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 6 | $0.20 | $0.29 | $0.24 |
| Q2 2017 | 3 | $0.22 | $0.24 | $0.23 |
| Q3 2017 | 3 | $0.29 | $0.31 | $0.30 |
| Q4 2017 | 2 | $0.32 | $0.32 | $0.32 |
| Q1 2018 | 3 | $0.40 | $0.43 | $0.41 |
| Q2 2018 | 3 | $0.32 | $0.38 | $0.35 |
| Q3 2018 | 3 | $0.46 | $0.50 | $0.48 |
| Q4 2018 | 3 | $0.50 | $0.61 | $0.55 |
| Q1 2019 | 2 | $0.58 | $0.61 | $0.60 |
| Q2 2019 | 1 | $0.51 | $0.51 | $0.51 |
| Q3 2019 | 1 | $0.63 | $0.63 | $0.63 |
| Q4 2019 | 2 | $0.65 | $0.82 | $0.74 |
(Data provided by Zacks Investment Research)
Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 89.69%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/30/2017 | Eric A Md Rose | Director | Sell | 982 | $145.17 | $142,556.94 | |
| 8/24/2017 | Eric A Md Rose | Director | Sell | 23,018 | $151.09 | $3,477,789.62 | |
| 8/15/2017 | Paul Thomas | Director | Sell | 10,000 | $154.71 | $1,547,100.00 | |
| 7/31/2017 | David M Weber | COO | Sell | 16,500 | $147.63 | $2,435,895.00 | |
| 5/16/2017 | Michael G Howley | VP | Sell | 18,279 | $133.56 | $2,441,343.24 | |
| 5/8/2017 | David M Weber | COO | Sell | 21,250 | $130.89 | $2,781,412.50 | |
| 5/8/2017 | Dorothy E Puhy | Director | Sell | 13,500 | $131.12 | $1,770,120.00 | |
| 5/8/2017 | Michael G Howley | VP | Sell | 600 | $132.84 | $79,704.00 | |
| 3/17/2017 | Andrew J Greenfield | VP | Sell | 10,000 | $124.00 | $1,240,000.00 | |
| 12/13/2016 | Dorothy E Puhy | Director | Sell | 8,000 | $120.00 | $960,000.00 | |
| 11/30/2016 | Eric A Md Rose | Director | Sell | 8,000 | $110.81 | $886,480.00 | |
| 9/22/2016 | Michael R Minogue | CEO | Sell | 28,039 | $127.07 | $3,562,915.73 | |
| 9/21/2016 | Michael R Minogue | CEO | Sell | 5,034 | $127.07 | $639,670.38 | |
| 9/19/2016 | Michael R Minogue | CEO | Sell | 58,710 | $127.00 | $7,456,170.00 | |
| 8/15/2016 | Dorothy E Puhy | Director | Sell | 5,160 | $123.94 | $639,530.40 | |
| 8/10/2016 | Dorothy E Puhy | Director | Sell | 3,900 | $122.31 | $477,009.00 | |
| 8/8/2016 | Michael G Howley | VP | Sell | 17,853 | $119.20 | $2,128,077.60 | |
| 8/1/2016 | Henri A Termeer | Director | Sell | 25,866 | $118.70 | $3,070,294.20 | |
| 6/29/2016 | Michael G Howley | VP | Sell | 10,000 | $106.58 | $1,065,800.00 | |
| 6/7/2016 | Andrew J Greenfield | VP | Sell | 9,000 | $104.16 | $937,440.00 | |
| 5/23/2016 | David M Weber | COO | Sell | 4,342 | $96.97 | $421,043.74 | |
| 5/16/2016 | David M Weber | COO | Sell | 5,604 | $94.56 | $529,914.24 | |
| 5/6/2016 | David M Weber | COO | Sell | 2,145 | $93.82 | $201,243.90 | |
| 5/5/2016 | David M Weber | COO | Sell | 52,000 | $95.27 | $4,954,040.00 | |
| 5/5/2016 | Paul Thomas | Director | Sell | 7,500 | $95.14 | $713,550.00 | |
| 4/18/2016 | Andrew J Greenfield | VP | Sell | 10,000 | $99.10 | $991,000.00 | |
| 4/13/2016 | Michael G Howley | VP | Sell | 9,800 | $98.64 | $966,672.00 | |
| 4/8/2016 | Michael G Howley | VP | Sell | 200 | $98.80 | $19,760.00 | |
| 4/1/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $95.02 | $950,200.00 | |
| 3/31/2016 | Andrew J Greenfield | VP | Sell | 15,000 | $94.11 | $1,411,650.00 | |
| 3/24/2016 | David M Weber | COO | Sell | 5,235 | $89.93 | $470,783.55 | |
| 3/22/2016 | Andrew J Greenfield | VP | Sell | 24,800 | $89.06 | $2,208,688.00 | |
| 3/22/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $90.30 | $903,000.00 | |
| 3/21/2016 | Andrew J Greenfield | VP | Sell | 19,572 | $89.07 | $1,743,278.04 | |
| 3/10/2016 | Andrew J Greenfield | VP | Sell | 200 | $89.00 | $17,800.00 | |
| 3/8/2016 | David M Weber | COO | Sell | 17,521 | $85.20 | $1,492,789.20 | |
| 3/8/2016 | William J Bolt | SVP | Sell | 17,510 | $85.19 | $1,491,676.90 | |
| 3/7/2016 | David M Weber | COO | Sell | 8,111 | $85.21 | $691,138.31 | |
| 3/7/2016 | Dorothy E Puhy | Director | Sell | 4,000 | $85.00 | $340,000.00 | |
| 3/7/2016 | William J Bolt | SVP | Sell | 7,987 | $85.20 | $680,492.40 | |
| 2/8/2016 | Dorothy E. Puhy | Director | Sell | 4,000 | $80.47 | $321,880.00 | |
| 8/19/2015 | Michael R. Minogue | CEO | Sell | 146,800 | $104.87 | $15,394,916.00 | |
| 8/17/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $103.91 | $268,087.80 | |
| 8/14/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $105.27 | $271,596.60 | |
| 7/17/2015 | Michael G Howley | VP | Sell | 21,295 | $70.00 | $1,490,650.00 | |
| 6/15/2015 | Andrew J Greenfield | VP | Sell | 3,185 | $65.00 | $207,025.00 | |
| 5/29/2015 | Martin P Sutter | Director | Buy | 7,500 | $60.17 | $451,275.00 | |
| 5/27/2015 | David M Weber | COO | Sell | 17,968 | $60.77 | $1,091,915.36 | |
| 5/12/2015 | Michael G Howley | VP | Sell | 17,353 | $66.47 | $1,153,453.91 | |
| 5/7/2015 | Andrew J Greenfield | VP | Sell | 3,500 | $71.00 | $248,500.00 | |
| 5/7/2015 | Robert Bowen | CFO | Sell | 2,372 | $71.52 | $169,645.44 | |
| 5/6/2015 | David M Weber | COO | Sell | 1,605 | $73.72 | $118,320.60 | |
| 5/6/2015 | Michael R Minogue | CEO | Sell | 8,840 | $73.12 | $646,380.80 | |
| 5/6/2015 | William J Bolt | SVP | Sell | 1,750 | $74.27 | $129,972.50 | |
| 3/23/2015 | David M Weber | COO | Sell | 3,765 | $71.08 | $267,616.20 | |
| 10/31/2014 | Andrew J Greenfield | VP | Sell | 15,000 | $31.90 | $478,500.00 | |
| 10/31/2014 | Michael R Minogue | CEO | Sell | 164,000 | $31.14 | $5,106,960.00 | |
| 7/28/2014 | Michael R Minogue | CEO | Sell | 82,383 | $26.30 | $2,166,672.90 | |
| 5/27/2014 | Andrew J Greenfield | VP | Sell | 7,026 | $21.10 | $148,248.60 | |
| 5/27/2014 | David M Weber | COO | Sell | 10,172 | $21.11 | $214,730.92 | |
| 5/27/2014 | Michael R Minogue | CEO | Sell | 90,001 | $21.19 | $1,907,121.19 | |
| 5/27/2014 | Robert Bowen | CFO | Sell | 6,820 | $21.11 | $143,970.20 | |
| 5/27/2014 | William J Bolt | SVP | Sell | 8,029 | $21.10 | $169,411.90 | |
| 5/15/2014 | David Weber | COO | Sell | 1,425 | $20.94 | $29,839.50 | |
| 5/15/2014 | Michael Howley | VP | Sell | 1,267 | $20.94 | $26,530.98 | |
| 5/15/2014 | Michael Minogue | CEO | Sell | 4,433 | $20.94 | $92,827.02 | |
| 5/15/2014 | William Bolt | SVP | Sell | 1,110 | $20.94 | $23,243.40 | |
| 1/10/2014 | Robert Bowen | CFO | Sell | 37,500 | $30.00 | $1,125,000.00 | |
| 9/3/2013 | David Weber | COO | Sell | 6,500 | $24.00 | $156,000.00 | |
| 9/3/2013 | William Bolt | SVP | Sell | 20,000 | $24.00 | $480,000.00 | |
| 8/14/2013 | William Bolt | SVP | Sell | 21,534 | $23.35 | $502,818.90 | |
| 8/13/2013 | David Weber | COO | Sell | 4,400 | $23.00 | $101,200.00 | |
| 8/13/2013 | Michael Howley | VP | Sell | 8,400 | $23.00 | $193,200.00 | |
| 8/5/2013 | David Weber | COO | Sell | 7,100 | $22.90 | $162,590.00 | |
| 8/5/2013 | Michael Howley | VP | Sell | 1,600 | $23.03 | $36,848.00 | |
| 8/5/2013 | Robert Bowen | CFO | Sell | 2,235 | $22.64 | $50,600.40 | |
| 8/5/2013 | W Gerald Austen | Director | Sell | 8,000 | $22.85 | $182,800.00 | |
| 8/5/2013 | William Bolt | SVP | Sell | 20,166 | $22.70 | $457,768.20 | |
| 7/31/2013 | Michael R Minogue | CEO | Sell | 36,500 | $25.04 | $913,960.00 | |
| 7/17/2013 | Michael G Howley | VP | Sell | 10,000 | $24.45 | $244,500.00 | |
| 7/15/2013 | Robert Bowen | CFO | Sell | 40,786 | $23.50 | $958,471.00 | |
| 7/11/2013 | Robert Bowen | CFO | Sell | 1,499 | $23.50 | $35,226.50 | |
| 6/4/2013 | David M Weber | COO | Sell | 6,519 | $21.20 | $138,202.80 | |
| 6/4/2013 | Michael G Howley | VP | Sell | 3,881 | $21.20 | $82,277.20 | |
| 6/4/2013 | Michael R Minogue | CEO | Sell | 17,667 | $21.23 | $375,070.41 | |
| 6/4/2013 | Robert Bowen | CFO | Sell | 5,298 | $21.20 | $112,317.60 | |
| 6/4/2013 | William J Bolt | SVP | Sell | 4,967 | $21.20 | $105,300.40 | |
| 5/29/2013 | Michael R Minogue | CEO | Sell | 58,833 | $21.83 | $1,284,324.39 | |
| 5/28/2013 | David M Weber | COO | Sell | 6,018 | $22.18 | $133,479.24 | |
| 5/28/2013 | Michael G Howley | VP | Sell | 5,476 | $22.18 | $121,457.68 | |
| 5/28/2013 | Robert Bowen | CFO | Sell | 5,102 | $22.18 | $113,162.36 | |
| 5/28/2013 | William J Bolt | SVP | Sell | 4,629 | $22.18 | $102,671.22 | |
| 5/23/2013 | Andrew J Greenfield | VP | Sell | 1,666 | $21.63 | $36,035.58 | |
| 5/23/2013 | Michael R Minogue | CEO | Sell | 5,666 | $21.62 | $122,498.92 | |
| 5/17/2013 | Robert Bowen | CFO | Sell | 2,715 | $23.50 | $63,802.50 | |
| 5/9/2013 | Michael R Minogue | CEO | Sell | 20,000 | $21.00 | $420,000.00 | |
| 5/7/2013 | Henri A Termeer | Director | Buy | 100,000 | $19.86 | $1,986,000.00 | |
| 2/25/2013 | Henri A Termeer | Director | Buy | 100,000 | $14.98 | $1,498,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ABIOMED (NASDAQ:ABMD)
Latest Headlines for ABIOMED (NASDAQ:ABMD)
| Source: |
|
| Date | Headline |
|---|
 | Mindray Medical International (MR) vs. ABIOMED (ABMD) Financial Review
www.americanbankingnews.com - September 23 at 4:22 AM |
 | Stock Exchange: Climbing The Wall Of Worry - Seeking Alpha
seekingalpha.com - September 22 at 3:03 PM |
 | Abiomed: Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
www.finanznachrichten.de - September 22 at 12:19 PM |
| Head-To-Head Review: ABIOMED (ABMD) and Its Rivals
www.americanbankingnews.com - September 22 at 10:30 AM |
| Abiomed receives FDA PMA approval for Impella RP for right heart failure; shares ahead 2% premarket
seekingalpha.com - September 21 at 8:53 AM |
 | Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure - GlobeNewswire (press release)
globenewswire.com - September 21 at 1:26 AM |
 | FDA Nod For ABMD, AERI Faces FDA Panel In Oct, IPCI Put On Notice, PFE Sues JNJ - Nasdaq
www.nasdaq.com - September 21 at 1:26 AM |
 | Abiomed (ABMD) Announces FDA PMA Approval for Impella RP for Right Heart Failure - StreetInsider.com
www.streetinsider.com - September 20 at 8:24 PM |
 | Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
finance.yahoo.com - September 20 at 8:24 PM |
| Zacks: Brokerages Anticipate ABIOMED, Inc. (ABMD) Will Announce Quarterly Sales of $130.37 Million
www.americanbankingnews.com - September 13 at 3:56 AM |
| ABIOMED, Inc. (ABMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 12 at 9:03 AM |
| $0.37 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - September 11 at 8:16 PM |
| ABMD Crosses Above Average Analyst Target
www.nasdaq.com - September 11 at 3:47 PM |
| Biolase (BIOL) vs. ABIOMED (ABMD) Head-To-Head Contrast
www.americanbankingnews.com - September 2 at 4:10 PM |
| ABIOMED, Inc. – Value Analysis (NASDAQ:ABMD) : September 2, 2017
finance.yahoo.com - September 2 at 1:54 AM |
| ABIOMED, Inc. (ABMD) Director Eric A. Md Rose Sells 982 Shares
www.americanbankingnews.com - September 1 at 8:30 PM |
| Harvard Bioscience (HBIO) & ABIOMED (ABMD) Critical Contrast
www.americanbankingnews.com - August 30 at 4:26 PM |
| ABIOMED, Inc. breached its 50 day moving average in a Bearish Manner : ABMD-US : August 30, 2017
finance.yahoo.com - August 30 at 3:21 PM |
| ABIOMED's (ABMD) Buy Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - August 30 at 2:28 PM |
 | Abiomed searches for new CFO after Tomsicek resigns - MarketWatch
www.marketwatch.com - August 30 at 1:49 AM |
| ABIOMED, Inc. (ABMD) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - August 29 at 1:04 PM |
| Abiomed (ABMD) CFO Resigns to Pursue Other Interests
www.streetinsider.com - August 29 at 1:38 AM |
| Abiomed (ABMD) CFO Resigns to Pursue Other Interests - StreetInsider.com
www.streetinsider.com - August 28 at 8:37 PM |
| Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant
finance.yahoo.com - August 28 at 8:37 PM |
| Abiomed searches for new CFO after Tomsicek resigns
finance.yahoo.com - August 28 at 8:37 PM |
| Eric A. Md Rose Sells 23,018 Shares of ABIOMED, Inc. (ABMD) Stock
www.americanbankingnews.com - August 28 at 7:20 PM |
| ABIOMED, Inc. (ABMD) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - August 26 at 7:52 PM |
| ABIOMED, Inc. (ABMD) Expected to Post Quarterly Sales of $130.37 Million
www.americanbankingnews.com - August 26 at 4:00 PM |
| Head to Head Survey: ABIOMED (ABMD) vs. PerkinElmer (PKI)
www.americanbankingnews.com - August 25 at 10:36 AM |
| ABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 18 at 8:38 AM |
| ABIOMED, Inc. (ABMD) Director Sells $1,547,100.00 in Stock
www.americanbankingnews.com - August 17 at 7:38 PM |
| ETFs with exposure to ABIOMED, Inc. : August 15, 2017
finance.yahoo.com - August 15 at 3:35 PM |
| IHS Markit Score Update: Drop in demand for ETFs holding Abiomed Inc is a negative sign for its shares
finance.yahoo.com - August 12 at 1:41 AM |
| Why ABIOMED (ABMD) Could Be Positioned for a Surge
finance.yahoo.com - August 10 at 4:49 PM |
| See what the IHS Markit Score report has to say about Abiomed Inc.
finance.yahoo.com - August 9 at 8:36 PM |
| ABIOMED, Inc. (ABMD) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - August 7 at 1:42 PM |
| $130.37 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - August 7 at 7:44 AM |
| ABIOMED, Inc. (NASDAQ:ABMD) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 6 at 8:12 AM |
| Brokerages Expect ABIOMED, Inc. (NASDAQ:ABMD) to Announce $0.37 EPS
www.americanbankingnews.com - August 5 at 10:38 PM |
| PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance
finance.yahoo.com - August 4 at 3:23 PM |
| Allscripts (MDRX) Meets Q2 Earnings Estimates, View Upbeat
finance.yahoo.com - August 4 at 3:23 PM |
| ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q1, 2018 By the Numbers : August 2, 2017
finance.yahoo.com - August 2 at 8:22 PM |
| ABIOMED, Inc. (NASDAQ:ABMD) COO Sells $2,435,895.00 in Stock
www.americanbankingnews.com - August 2 at 7:26 PM |
| DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - August 2 at 3:19 PM |
| Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y
finance.yahoo.com - August 2 at 3:19 PM |
| Quality Systems (QSII) Beats on Q1 Earnings, Revenues
finance.yahoo.com - August 2 at 3:19 PM |
| Q4 2018 EPS Estimates for ABIOMED, Inc. Lifted by Leerink Swann (NASDAQ:ABMD)
www.americanbankingnews.com - July 31 at 10:06 AM |
| William Blair Research Analysts Lift Earnings Estimates for ABIOMED, Inc. (NASDAQ:ABMD)
www.americanbankingnews.com - July 31 at 9:04 AM |
| Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates - Nasdaq
www.nasdaq.com - July 28 at 3:39 PM |
| Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates
finance.yahoo.com - July 28 at 3:39 PM |
ABIOMED (ABMD) Chart for Tuesday, September, 26, 2017
